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Abstract (247/250 words) 28 
Background: The hepatotoxicity of acetaminophen is recognized worldwide. Unfavourable prognoses 29 
relating to overdose include liver transplantation and/or death. Several hepatotoxicity risk factors 30 
(HRFs) should motivate the adjustment of acetaminophen daily intake (to < 4 g/day): advanced age, 31 
weight < 50 kg, malnutrition, chronic alcoholism, chronic hepatitis B and C and HIV infection, severe 32 
chronic renal failure, and hepatocellular insufficiency. 33 
Method: Over a seven-day period in Rennes University Hospital in December 2017, using DxCare® 34 
software, with an odds ratio estimation, we analysed all acetaminophen prescriptions, to assess to 35 
what extent the presence of HRFs altered the prescribers’ choice of acetaminophen dose (< 4 g/day 36 
versus 4 g/day). 37 
Results: Among 1842 patients, considering only the first acetaminophen prescription, 73.7 % were on 38 
4 g/day. Almost half this population had at least 1 HRF. Whereas around 80 % of the prescriptions in 39 
the < 4 g/day group were for patients with at least 1 HFR, only 53 % of the prescriptions in the 40 
4 g/day group concerned patients without HFRs (p < 0.001). Age > 75 and low weight were associated 41 
with the prescriber’s choice of dose. Neither chronic alcoholism nor hepatocellular insufficiency 42 
influenced the acetaminophen doses prescribed. 43 
Conclusion: Considering the widespread use of acetaminophen and its favourable safety profile 44 
compared to other analgesic drugs, it appears urgent to remind prescribers of the maximum daily 45 
dose recommendations for acetaminophen for patients with HRFs, especially those with chronic 46 
alcoholism and hepatocellular insufficiency. 47 
  48 
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What is already known about this subject: 49 
 Acetaminophen is widely known to be a hepatotoxic drug. 50 
 Recommendations include a maximum daily dose of acetaminophen of < 4 g/day for patients 51 
with hepatotoxicity risk factors (chronic alcoholism, hepatocellular insufficiency, advanced 52 
age, anorexia…). 53 
 Studies have described up to 21 % of acetaminophen prescriptions without dose adjustment 54 
among patients with hepatotoxicity risk factors. 55 
 56 
What this study adds: 57 
 Age >75 and weight <50 kg are linked to prescriptions of < 4 g/day. 58 
 Chronic alcoholism, hepatocellular insufficiency, severe chronic renal failure, chronic viral 59 
infections and malnutrition have no influence on the choice of the dose. 60 
 Clinicians should systematically assess patient history, checking for any hepatotoxicity risk 61 
factors when prescribing acetaminophen. 62 
  63 
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Introduction  64 
Acetaminophen, also known as “paracetamol”, is the most widely prescribed first-line analgesic 65 
worldwide. Available as an over-the-counter drug in many countries such as France or the United 66 
States, it appears as the most frequent medication involved in both intentional and unintentional 67 
drug poisoning, according to the annual report by the American Association of Poison Control Center 68 
Data System and the French Addiction Monitoring Network[1, 2]. 69 
In case of acetaminophen accumulation and overdose, the main expected adverse effect is acute 70 
liver failure, including fulminant hepatitis, which can lead to liver transplantation and/or death[1, 3–71 
5]. The hepatotoxicity mechanism involves a CYP 450 (mainly 2E1) highly reactive converted 72 
metabolite, namely N-acetyl p-benzoquinone imine (NAPQI). NAPQI is physiologically broken down 73 
by gluthatione in the liver and excreted in the urine. However, in case of acetaminophen overdose, 74 
NAPQI production increases and exceeds the conjugation abilities of glutathione; as it binds to the 75 
hepatocellular membrane proteins, it induces liver parenchymal cell death[6].  76 
For a mean adult weight, clinical symptomatic acetaminophen hepatotoxicity is usually expected 77 
after a single acetaminophen ingestion of around 10 grams per 24 hours or 150 mg/kg, with an initial 78 
phase of cytolysis occurring in the first 24 to 48 hours. The hepatotoxicity is dose-dependent and can 79 
be predicted by a nomogram[7]. Immediately after an acetaminophen overdose, N-acetylcysteine is 80 
used to restore glutathione reserves which can limit hepatotoxicity[8] with recovery expected in 4-5 81 
days where the prognosis is favourable[9]. Studies have shown that advanced age, chronic alcohol 82 
consumption, as well as fasting/anorexia and poor nutritional status could be associated with 83 
gluthatione depletion; it is worth noting that chronic alcohol consumption has also been shown to be 84 
a CYP 2E1 inducer leading to NAPQI increase[10–12]. Chronic renal failure as well as chronic liver 85 
disease (hepatic failure, cirrhosis, viral hepatitis) are also considered to be acetaminophen 86 
hepatotoxicity risk factors (HRFs)[13–16] and should lead to an adjustment of acetaminophen daily 87 
intake. Meanwhile, case reports of hepatitis observed at therapeutic doses of 3 or 4 g/day have been 88 
reported among patients with low weight, a history of chronic alcoholism, hepatic steatosis or recent 89 
fasting[17–21]. Furthermore, certain randomised controlled trials have reported an increase (mostly 90 
3 to 4 times the normal upper limit) in serum alanine aminotransferase activity (ALT) for a significant 91 
proportion of ‘healthy’ patients exposed to acetaminophen at 4 g/day for several days, compared to 92 
placebo[22, 23], although the clinical significance is uncertain.  93 
Recommendations have been established for acetaminophen prescription, with a maximum daily 94 
dose of 4 grams, and they include dose adjustment for patients with HRFs[24–26]. Dose adjustments 95 
are detailed in most summary of product characteristics (SmPC) for acetaminophen-based 96 
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medications. A lack of accurate and harmonised information across SmPC is however observed. In 97 
general terms, it is recommended to use the “lowest possible dose” for symptom relief and make 98 
gradual adaptation of the dose to the pain. Regarding the maximum acetaminophen dose, some 99 
SmPC mention that “it is generally not necessary to exceed 3 g per 24 hours”. Regarding dose 100 
adjustments for special populations (liver failure, renal failure, dehydration, weight <50 kg…), 101 
although it is formulated differently across SmPC, it is recommended to use the lowest possible 102 
effective doses, and specifically to increase interval between two intakes (>8h) in severe chronic 103 
renal failure. The maximum recommended doses in special population are given as an indication 104 
(sometimes 2g/day or 3g/day) but are not necessarily related to clinical studies (no reference 105 
provided in SmPC).” 106 
Few studies have described acetaminophen prescription patterns in hospitals or assessed  107 
compliance with recommendations relating to HRFs: in French and American cohorts, failure to 108 
adjust doses in view of the presence of HRFs was observed in 1 % to 21 % of prescriptions[27–31]. It 109 
can be noted that neither the type of hospital units (surgery, geriatrics...) nor pharmaceutical 110 
validation studies have an influence on dose adjustment[27, 30].  111 
This work was performed after the notification in our local Pharmacovigilance unit of cases of 112 
acetaminophen toxicity at doses in the therapeutic range among patients with HRFs: the most 113 
recent, with a fatal outcome, concerned a 72-year-old hospitalised man who developed cytolysis 114 
with acute hepatic failure two days after the initiation of 4 g/day acetaminophen for acute pain. The 115 
patient’s history included alcoholism and cachexia, in a context of hepatic steatosis, septic shock and 116 
the discovery of metastatic colorectal cancer. 117 
As we believe that some HRFs are more likely to induce dose adjustments than others, the aim of our 118 
study was to assess to what extent the existence of HRFs (single or in combination) modify the 119 
prescribers’ choice of acetaminophen dose (< 4 g/day versus 4 g/day). 120 
  121 
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Materials and methods 122 
We conducted a retrospective monocentric cross-sectional study including all patients with an 123 
acetaminophen prescription in  Rennes University Hospital. 124 
All data was collected in accordance with the French legislation on retrospective clinical studies, in 125 
accordance with the precepts established by the Helsinki declaration. 126 
 127 
 Data sources 128 
The extraction of data concerning acetaminophen prescriptions (oral and intravenous) (Dxcare® 129 
software version 7.5.20p049, Medasys®) was carried out over one week, from the 13th to the 19th 130 
December 2017. Only patients aged over 18 years, i.e. born after 12/12/1999, were considered for 131 
this analysis.  132 
 133 
 Exposure 134 
All medications containing acetaminophen were considered, precribed on their own or in 135 
combination with other drugs. We collected the names of the medications, the routes of 136 
administration and the daily doses. Patients were categorised as having a maximum dose of 4 g/day 137 
or less than 4 g/day. The patients for whom the dose was specified as “1 g ‘upon request’, maximum 138 
4 times a day,” were considered as having the maximum 4 g/day dose. 139 
 140 
 Other variables 141 
Data was collected from the patients' electronic files: age at the time of the acetaminophen 142 
prescription, gender, hospital unit, weight, body mass index, biological parameter values (serum 143 
creatinine, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 144 
phosphatase (PAL), gamma-glutamyl transpeptidase (GGT), direct bilirubin, total bilirubin, 145 
prothrombin time (TP), international normalised ratio (INR), factor V, serum albumin and pre-146 
albumin), the presence of chronic viral hepatitis (B or C) and human immunodeficiency virus (HIV), 147 
current chronic alcoholism, current intake of oral anticoagulants, current malnutrition, history of liver 148 
or renal transplantation. 149 
 150 
 151 
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 Risk factors predisposing to hepatotoxicity 152 
According to the SmPC and French recommendations on acetaminophen prescription [24–26], we 153 
considered seven HRF categories that should lead to dose adjustment, defined as followed:  154 
- age over 75 years, i.e. patients born before the 12th December 1942; 155 
- low weight: under 50 kg; 156 
- malnutrition defined by the presence of one or more of the following criteria: serum albumin 157 
< 30 g / L, serum pre-albumin <150 mg / L, BMI < 18.5 for patients < 70 years old, BMI < 21 158 
for patients  70 years old, the specific mention of “malnutrition” in the electronic file;  159 
- chronic alcoholism: we selected patients whose electronic file records specified excessive 160 
and chronic alcohol consumption; 161 
- current chronic viral infections (hepatitis B, C and/or D) and/or HIV; patient status was 162 
individually checked by a virologist (CP author). HIV patients with an undetectable viral load 163 
were considered as presenting a risk factor; patients who had recovered from hepatitis C at 164 
study entry were not considered as presenting a risk factor; 165 
- severe chronic renal failure defined by a creatinine clearance value (estimated by the CKD-166 
EPI equation) of < 30 ml / min in the electronic file; 167 
- hepatocellular insufficiency, biologically defined by one or more following abnormalities: 168 
factor V < 70 %, prothrombin time decrease, INR > 1.5 for patients without anticoagulant 169 
treatment or INR > 5 with anticoagulant treatment, ALT > 40 UI/L, AST > 40 UI/L. Other 170 
biological parameters were considered only in case of association with other abnormalities: 171 
serum albumin concentration < 35 g / L and/or the following clinical signs specified in the 172 
electronic file: “jaundice”, “hepatic encephalopathy”, “cirrhosis”, “stellate angioma” or 173 
“palmar erythrosis”, “alcoholic hepatitis”, “viral hepatitis”. 174 
 175 
 Statistical methods 176 
In case of several acetaminophen prescriptions for the same patient, only the first was considered for 177 
the descriptive and statistical analyses in order to ensure the independence of the data and analyses. 178 
We considered the first prescription as the initial prescriber’s intention to treat, as the second or 179 
following prescriptions could be related to  medical or pharmaceutical re-assessment. 180 
Descriptive statistics characterised patients at the time of the 1st acetaminophen prescription. 181 
Proportions were compared across levels of exposure using chi-square tests or Fisher’s exact test; 182 
age was compared using the Student t test. 183 
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A logistic regression model considering all HRFs was used to estimate those that were significantly 184 
related to the prescribers’ choice of acetaminophen dose (< 4 g/day versus 4 g/day). 185 
A descending step-by-step selection model was used, retaining only the variables (HRF) significantly 186 
associated with acetaminophen dose adjustment (< 4 g/day) at a 5 % statistical threshold. 187 
An odds ratio estimation was used to determine which HRFs were associated with dose adjustment 188 
(< 4 g/day or 4 g/day) in the prescribers’ prescriptions. 189 
All analyses were conducted using the SAS statistical package (version 9.4; SAS Institute, Cary, NC, 190 
USA).  191 
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Results 192 
Over a seven-day period in December 2017, 2338 acetaminophen prescriptions were collected from 193 
Rennes University Hospital. After excluding prescriptions for patients under 18 years, 2048 194 
acetaminophen prescriptions concerning 1842 patients were included in this study. Retaining only 195 
the first prescription for each patient, 1842 prescriptions were used for the analyses (see Figure 1). 196 
The characteristics of the study population are displayed in table 1. Around 54 % were female. The 197 
median age was 65 years (min 18 years – max 101 years) and 32.9 % were over 75 years old.  198 
Among the 1842 prescriptions, 73.7 % were for 4 g/day (table 1); it can be noted that no prescription 199 
exceeded the maximum 4-g daily dose. Females were more frequently in the < 4 g/day group than in 200 
the 4 g/day group (60.1 % vs 51.3 %, p < 0.001). Regarding the hospital unit, in the < 4 g/day group, 201 
prescribers mainly belonged to geriatric or other clinical units (respectively 44.6 % and 41.1 %); in the 202 
4 g/day group, prescriptions mainly derived from surgery / anaesthesia / intensive care / palliative 203 
units and other clinical units (respectively 57.1 % and 32.6 %). 204 
Around 55 % of the overall population presented with at least one HRF. Among patients with only 205 
one HRF (n = 549), the HRF was mainly age > 75 years, and secondarily hepatocellular insufficiency or 206 
chronic alcoholism (appendix table 1). Whereas around 80 % of prescriptions in the < 4 g/day group 207 
were for patients with at least 1 HFR, only 53 % of prescriptions in the 4 g/day group concerned 208 
patients without any HFR (p < 0.001). Furthermore, some HRFs were significantly more frequent in 209 
the < 4 g/day group (table 1) : age > 75, low weight, malnutrition and severe renal failure. 210 
Concerning the statistical analysis, only prescriptions without missing data on the HRF category were 211 
used (n = 1103), including 363 patients in the < 4 g/day group and 740 in the 4 g/day group. The 212 
logistic regression showed that age > 75 and low weight were significantly associated with the 213 
prescriber’s choice of dose (table 2). The descending step-by-step model confirmed that only age > 214 
75 and low weight remained significantly associated with the < 4 g/day dose (data not shown). We 215 
observed similar results in a sensitivity analysis using age > 75 and weight as continuous variables 216 
(data not shown).  217 
It can be noted that among  patients > 75 years (n = 606), who accounted for one-third of the overall 218 
population, all had 1 (n = 315) or 2 (n = 291) HRFs. Despite this, around 50 % (n = 302) had no dose 219 
adjustment. 220 
As regards the administration route, 63 (3,4 %) concerned intravenous use, most of whom (86 %; 221 
n=54) had a 4 g/day dose. In those patients, at least one HRF was recorded in 34 patients. As regards 222 
the 9 patients in the < 4 g/day group, 1 had no HRF, 2 had only one HRF (age > 75 in both cases) and 223 
Revised manuscript 
 
Bacle et al.  10 
7 had at least 2 HRF. More in depth, Paracetamol B Braun 1g/100 ml (adult formulation) was used in 224 
all cases. Its SmPC recommends a dose adjustment considering weight category (between 33 and 50 225 
kg or > 50 kg) and whether HRF are present (chronic alcoholism, hepatocellular insufficiency, chronic 226 
malnutrition, and dehydration for which maximal dose is 3 g/day). 227 
 228 
  229 
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Discussion 230 
In our seven-day study focusing on acetaminophen prescriptions in Rennes University Hospital, 231 
around three quarters of prescriptions were full-dose (4 g/day); in this group, 47 % of prescriptions 232 
were for patients with at least one HRF: these can be considered as non-compliant prescriptions, and 233 
the proportion is greater than in previous studies showing up to 21 % of non-compliant 234 
acetaminophen prescriptions in hospital[27–31]. The lower non-compliant prescriptions could be 235 
related to the fact that age > 75 years is not considered as a HRF in SmPC and no dose adjustment is 236 
recommended. As mentioned by Pacé et al., medicine and geriatric units seem to be more aware of 237 
the HRFs of acetaminophen[31]: in our study the number of prescriptions for < 4 g/day in these units 238 
amounted to around 85 % of the prescriptions. 239 
For the HRFs studied, we showed that age > 75 years and low weight influenced the prescribers' 240 
choice of dose. The impact of advanced age here could be linked to age in our cohort since the 241 
median age was 65.0 years and one third of the patients were over 75 years old. Another explanation 242 
linked to age is the fact that, in Rennes University Hospital, prescribers are particularly aware of 243 
dosage adjustment for elderly patients thanks to careful monitoring by the pharmacists. Surprisingly, 244 
neither chronic alcoholism nor hepatocellular insufficiency were associated with dose adjustment. 245 
Although acetaminophen is a highly hepatotoxic drug and its metabolism involves the liver, 246 
prescribers appear not to consider these HRFs in their choice of dose. Hepatic tests after 247 
acetaminophen initiation were not performed in our study, so we could not check for clinical or 248 
biological signs of hepatotoxicity among patients with these HRFs. Pace et al. also observed a high 249 
rate of non-compliance with recommendations (> 68 %) for patients with chronic alcoholism or 250 
hepatocellular insufficiency[31], suggesting that prescribers need to be made aware of dose 251 
adjustments in these patient groups. Unlike our study where low weight was a dose-adjustment 252 
variable in acetaminophen prescriptions by clinicians, this factor was explored in heterogeneous 253 
manner in other studies and was related to non-compliance[29, 31]. 254 
None of the prescriptions exceeded the 4-g per day, which is no doubt linked to  the use of software 255 
(DxCare) limiting acetaminophen daily doses; a warning is also displayed when several drugs 256 
containing acetaminophen are coprescribed. 257 
Some HRF as well as their definition can be discussed. In a literature review, Caparrotta et al. found 258 
no good quality evidence to establish that factors were HRF[11]. They notably pointed that the safe 259 
oral acetaminophen dose in patients < 50 kg had not been established. In our study, chronic 260 
alcoholism status has only been identified through a subjective HRF reading (potentially 261 
underestimated) without re-assessment by an independent committee. No additional information 262 
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was collected (severity, care…). Age, especially advanced age is described as HRF whereas literature 263 
data are inconsistent (PK, case series, population-based studies)[11, 12]. As evoked by Caparrotta et 264 
al. there is a lack of good quality clinical evidence that older people have a clinically significant 265 
difference in acetaminophen metabolism or are at increased risk of toxicity at (supra)therapeutic 266 
dose. Age cut-off also varied across studies[12, 32–34]. Moreover, neither French SmPC nor 267 
recommendations provide an age cut-off. Considering that “old age” definition is complex, 268 
potentially subjective (physical, psychological conditions), and is not only related to years, we 269 
arbitrarily chose 75 years-old as cut-off in our study. In addition to biological criteria, hepatocellular 270 
insufficiency definition also included a HRF reading seeking specific terms (cirrhosis, hepatic 271 
encephalopathy) without secondary objective re-assessment. All these limitations could have 272 
induced misclassification bias of HRF. 273 
The main strength of our work lies in the data collection that took place within a week and involved 274 
all adult patients’ electronic files in all Rennes University Hospital units. Among the weaknesses, we 275 
recognize that our results concern only one hospital and may not be representative of French 276 
hospital prescribers. But the objective of our study was not to compare with practices in other 277 
hospitals but rather to highlight the fact that HRFs are not always considered by prescribers,  even in 278 
university hospitals, when prescribing acetaminophen. Nor did we consider the indication for 279 
acetaminophen, treatment duration or the potential need for opioid treatments, which could have 280 
impacted dose adjustment. Considering a safety approach, we deliberately focused our study on the 281 
first acetaminophen dose prescribed, irrespective of its indication, as representing intention-to-treat. 282 
Furthermore, our statistical analysis did not include all the 1842 prescriptions in the overall 283 
population as a result of missing data for some HRFs: around 33 % of patients had missing data for 284 
the hepatocellular insufficiency variable, and 10 % for malnutrition status. It can be noted that some 285 
HRFs could have been under-estimated, especially alcoholism which is often concealed by patients 286 
when questioned on the subject. We did not assess either whether the 4g/day dose for patients with 287 
one or more HRF had clinical significance for liver function, nor did we consider the type of HRF; 288 
indeed, hepatic cytolysis is more likely among patients with cirrhosis than among elderly patients 289 
without other liver diseases. We did not consider co-medication and especially drug-drug interaction, 290 
nor other clinical conditions (sepsis, heart failure[35, 36]) that affect the hepatic enzymes. In 291 
acetaminophen SmPCs, drug interaction section mentioned a precaution of use when associated with 292 
other hepatotoxic drugs or CYP 450 drug enzyme inducers. However, on the basis of the French drug-293 
drug interaction referential provided by the French Health Authorities (French National Agency for 294 
Medicines and Health Products Safety [ANSM])[37], no clinically significant interaction with 295 
paracetamol was highlighted, even with drugs impacting CYP 2E1 (doxycycline, isoniazide).  296 
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We should bear in mind that although acetaminophen is the most widely recognized drug in inducing 297 
liver damage[38, 39], its use is commonplace, mainly as a result of a good reputation with regard to 298 
safety compared to other analgesic drugs (non-steroid anti-inflammatory drugs for example). In 299 
order to limit the risk of poisoning and suicide using acetaminophen, France was the first country in 300 
Europe in the 1980s to limit packaging to a maximum dose of 8 grams of acetaminophen. In the 301 
2000s, the Federal Drug Agency in the United States and the United Kingdom Health Authorities also 302 
restricted the acetaminophen pack size[40, 41]; the FDA also limited the acetaminophen dosage unit 303 
to 325 mg in 2011[42, 43]. Despite this, acetaminophen remains the first drug involved in overdose 304 
(intentional or otherwise)[1, 2]. In 2017, W. Lee described the controversy surrounding 305 
acetaminophen use in pain management[9]: he pointed out that worldwide regulatory efforts had 306 
been ineffective in reducing the cost in money and lives resulting from its hepatotoxicity. In France, 307 
however, the French Pharmacovigilance network regularly collects case reports of acute 308 
acetaminophen poisoning. A recent fatal case in December 2017, which was highly publicized across 309 
France, led the Health Authorities to reinforce the data available on acetaminophen-based drugs: the 310 
objective was to raise awareness among patients and prescribers about liver damage. A public 311 
consultation was thus initiated on August 20th, 2018, ending on September 30th, 2018 for the 312 
definition of the best warning message to put on drug packaging[44]; but the results have not yet 313 
been issued. With the exception of hepatocellular insufficiency, there is a lack of information on dose 314 
adjustment, special warnings or contraindications in case of other HRFs with some acetaminophen-315 
based medications (e.g. Paracetamol Teva 1g, tablets; Paracetamol EG 500 mg/30 mg, effervescent 316 
scored tablets ; Paracetamol Zydus 500 mg, gelules …[45–47]). It is worth noting that maximum 317 
dose could vary from one SmPC to another: for instance, in case of HRF, 2g/day is mentioned in 318 
Paracetamol AHCL 1g, effervescent tablet[48] compared to 3g/day in Doliprane 1 g, tablets[49]. In 319 
general terms, lack of SmPC harmonisation, especially regarding the appropriate maximal dose to be 320 
used in case of HRF is a limitation for clinicians’ prescriptions compliance. ANSM planned a 321 
harmonisation of the warnings included in the SmPC for acetaminophen-based drugs in 2019. 322 
Considering pharmacovigilance cases report of acetaminophen toxicity in patients with HRF treated 323 
with (sub)therapeutic ⩽ 4 g/day dose and the results of the current study, in Rennes University 324 
Hospital, several improvement measures are planned: awareness raising at the residents’ welcome 325 
seminars twice a year, poster campaign in clinical departments, configuration of software as regards 326 
prescription schemes, awareness raising of pharmacist responsible of prescriptions’ pharmaceutical 327 
validation. 328 
  329 
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Conclusion 330 
This work shows that in Rennes University Hospital, HRFs are not systematically considered by 331 
clinicians when acetaminophen is prescribed. Age > 75 years and low weight had a greater impact on 332 
acetaminophen prescription than alcoholism, malnutrition, chronic viral hepatitis, severe renal 333 
failure or hepatocellular insufficiency. Considering the widespread use of acetaminophen, it appears 334 
important to remind healthcare professionals and patients of the hepatotoxicity risk resulting from 335 
misuse, especially in presence of HRF.  336 
  337 
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